Story excerpt provided by Crain’s Cleveland Business.
A Cleveland startup called Abeona Therapeutics, created around intellectual property licensed from Nationwide Children’s Hospital to develop treatments for Sanfilippo Syndrome Types A and B, said it has been granted orphan drug designations by the U.S. Food and Drug Administration for its lead investigational therapies.
“The FDA’s approval of our request for orphan drug designation is an important regulatory milestone for Abeona that supports our strategy for treating these devastating diseases,” said Tim Miller, Abeona’s president and CEO, in a statement.
Click here to read the complete article.
Originally published May 12, 2014.